References
- Cani PD . Human gut microbiome: hopes, threats and promises. Gut67 ( 9 ), 1716 – 1725 (2018).
- Lynch SV , PedersenO. The human intestinal microbiome in health and disease. N. Engl. J. Med.375, 2369 – 2379 (2016).
- Romero-Gomez M , MontagneseS, JalanR. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. J. Hepatol.62, 437 – 447 (2015).
- Adolph TE , GranderC, MoschenARet al. Liver-microbiome axis in health and disease. Trends Immunol.39 ( 9 ) 712 – 723 (2018).
- Backhed F , DingH, WangTet al. The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl Acad. Sci. USA101, 15718 – 15723 (2004).
- Li Z , YangS, LinHet al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology37, 343 – 350 (2003).
- Loomba R , SeguritanV, LiWet al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab.25, 1054 – 1062 (2017).
- Hoyles L , Fernandez-RealJM, FedericiMet al. Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women. Nat. Med.24, 1070 – 1080 (2018).
- Sabino J , Vieira-SilvaS, MachielsKet al. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. Gut65, 1681 – 1689 (2016).
- Kummen M , HolmK, AnmarkrudJAet al. The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. Gut66, 611 – 619 (2017).
- van den Bogert B , MeijerinkM, ZoetendalEGet al. Immunomodulatory properties of Streptococcus and Veillonella isolates from the human small intestine microbiota. PLoS ONE9, e114277 (2014).
- Qin N , YangF, LiAet al. Alterations of the human gut microbiome in liver cirrhosis. Nature513, 59 – 64 (2014).
- Atarashi K , SudaW, LuoCet al. Ectopic colonization of oral bacteria in the intestine drives TH1 cell induction and inflammation. Science358, 359 – 365 (2017).
- Tripathi A , DebeliusJ, BrennerDAet al. The gut–liver axis and the intersection with the microbiome. Nat. Rev. Gastroenterol. Hepatol.15, 397 – 411 (2018).
- Bischoff SC , BarbaraG, BuurmanWet al. Intestinal permeability – a new target for disease prevention and therapy. BMC Gastroenterol.14, 189 (2014).
- Tilg H , WilmerA, VogelWet al. Serum levels of cytokines in chronic liver diseases. Gastroenterology103, 264 – 274 (1992).
- Schierwagen R , Alvarez-SilvaC, MadsenMSAet al. Circulating microbiome in blood of different circulatory compartments. Gut26, doi:10.1136/gutjnl-2018-316227 (2018) ( Epub ahead of print).
- Lelouvier B , ServantF, PaisseSet al. Changes in blood microbiota profiles associated with liver fibrosis in obese patients: a pilot analysis. Hepatology64, 2015 – 2027 (2016).
- Puri P , DaitaK, JoyceAet al. The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids. Hepatology11, doi:10.1002/hep.29359 (2017) ( Epub ahead of print).
- Manfredo Vieira S , HiltenspergerM, KumarVet al. Translocation of a gut pathobiont drives autoimmunity in mice and humans. Science359, 1156 – 1161 (2018).
- Ren Z , LiA, JiangJet al. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut doi:10.1136/gutjnl-2017-315084 (2018) ( Epub ahead of print).
- Ponziani FR , BhooriS, CastelliCet al. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in non-alcoholic fatty liver disease. Hepatology17, doi:10.1002/hep.30036 (2018) ( Epub ahead of print).